Overview

A class action lawsuit has been filed against Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA) and certain of the Company’s former senior executive officers alleging violations of the federal securities laws.  The Moderna class action lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, both dates inclusive (the “Class Period”).  Investors have until October 8, 2024, to seek appointment as lead plaintiff of the Moderna class action lawsuit.

Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA (“mRNA”) therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.  The Company’s products include, inter alia, mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (“RSV”) vaccine, intended to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.  In July 2023, Moderna initiated a rolling submission of a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”).  This is the process by which, in Moderna’s case, a pharmaceutical company may submit completed sections of a BLA for review by the FDA before all sections become available-for real-time review of mRNA-1345 backed by late-stage data, which, in turn, indicated a vaccine efficacy rate of 83.7% as defined by two or more RSV symptoms related to the lower respiratory tract.

The Moderna class action lawsuit alleges that Defendants, throughout the Class Period, made materially false and misleading statements regarding the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) mRNA-1345 was less effective than Defendants had led investors to believe; (2) accordingly, mRNA-1345’s clinical and/or commercial prospects were overstated; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times. 

*          *          *

If you purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as a lead plaintiff in the Moderna class action lawsuit is October 8, 2024.